Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Recent Lucentis EU approval in new choroidal neovascularization (CNV) indication demonstrates Novartis’ strong commitment to innovate and grow Lucentis (ranibizumab) as standard of care in diseases of the retina [..]